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Received September 27, 2011; accepted January 5, 2012AbstractBackground: Preventing and managing hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is an important public health issue
worldwide, and Taiwan is one of the countries where viral hepatitis is most endemic. Previous studies have shown that patients with serious
mental illnesses have a higher risk for hepatitis infection. We investigated the prevalence of HBVand HCVamong institutionalized patients with
chronic schizophrenia in Taiwan.
Methods: A total of 590 patients were recruited into the study. HBV surface antigen, HCV antibody, and liver function were determined for all
participants.
Results: The seroprevalence of HBV surface antigen was 10.4% (males 12.6%, females 7.0%), and that of anti-HCV was 1.9% (males 2.6%,
females 0.8%).
Conclusion: Our study showed that the prevalences of HBVand HCVamong institutionalized patients with chronic schizophrenia were no higher
than the prevalences in the general population in Taiwan. The commodious environment and medical resources of the hospital where the patients
were living might have prevented an elevation of HBV and HCV infection in those with schizophrenia, supplementing the continuing benefits
from the HBV vaccination that was introduced in 1984.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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July 28, 2011 was designated by the World Health
Organization (WHO) as the first annual World Hepatitis
Day, in order to increase global awareness of the problem of
hepatitisdnearly one out of every three people in the world
has been infected by hepatitis virus. According to the most
recent WHO report, approximately 2 billion people worldwide* Corresponding author. Dr. Tsuo-Hung Lan, Department of Psychiatry,
Taichung Veterans General Hospital, 160, Section 3, Chung-Kang Road,
Taichung 407, Taiwan, ROC.
E-mail address: tosafish@gmail.com (T.-H. Lan).
1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2012.03.002have been infected with hepatitis B virus (HBV), and an
estimated 600,000 people die every year due to the acute or
chronic consequences of hepatitis B. At any given time, about
130e170 million people are chronically infected with hepatitis
C virus (HCV), and more than 350,000 people die from
hepatitis C-related liver diseases each year.1 The statistics
suggests that there is a further need to prevent, screen for, and
intervene early cases of HBV and HCV infection.
The prevalence of chronic HBV infection is about 5%
worldwide, but this figure varies substantially between
regions. Infection rates are low (0.1e2.0%) in the United
States and Western Europe, intermediate (2.0e8.0%) in
Mediterranean countries and Japan, and high (8.0e20.0%) inhinese Medical Association. All rights reserved.
Table 1
The demographic data of schizophrenia patients in this study.
Demographic data n %
Gender Female 242 41.0
Male 348 59.0
Age level 20e29 34 5.8
30e39 186 31.5
40e49 203 34.4
50e59 126 21.4
60e69 33 5.6
70 8 1.4
Education years Elementary school 110 19.1
Junior high school 148 25.7
Senior high school 198 34.4
College 70 12.2
Others or illiteracy 50 8.7
History of alcohol use No 421 71.5
Yes 168 28.5
Current alcohol use No 583 99.5
Yes 3 0.5
History of cigarette use No 305 51.8
Yes 284 48.2
Current cigarette use No 322 54.9
Yes 265 45.1
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is of epidemic proportions worldwide. Countries with high
rates of chronic infection are Egypt (22%), Pakistan (4.8%),
and China (3.2%).1 Taiwan is among the countries where the
infection is highly prevalent, with 15e20% of the general
population suffering from chronic HBV infection3e6 and an
estimated 4.4% of the general population with chronic HCV
infection.6
Previous studies have reported a higher infection rate with
HBV and HCV in specific groups, such as parenteral drug
users, male homosexuals, immunosuppressed patients, those
with hemophilia, and patients undergoing dialysis. A higher
incidence of hepatitis has also been identified in healthcare
workers, ambulance personnel, teachers, and staff in institu-
tions such as retirement homes and institutions for the intel-
lectual disability7e9 and those suffering serious mental
illness.10e12 Associated with their psychiatric impairment,
persons with severe mental illness are at an increased risk
for several co-morbid conditions, including substance use
disorder.13 They are also likely to be overrepresented in high-
risk categories for infections such as HBV and HCV.11
However, few studies have focused on HBV and HCV
infection rates among institutionalized patients with severe
mental illness, especially in a country with a high prevalence
of HBV. In an attempt to further assist in the prevention and
control of such an important public health concern, we con-
ducted a study to investigate the prevalence of HBV and HCV
infection in subjects with and without impaired liver function
among institutionalized schizophrenic patients in Taiwan.
2. Methods2.1. SubjectsIn this study, 590 patients who met the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, text
revision (DSM-IV-TR)14 criteria for schizophrenia were
recruited from the Yuli Veterans Hospital, a facility that is
affiliated to one of the largest mental hospitals in Taiwan. The
Yuli Veterans Hospital is operated under the concept of ther-
apeutic communities.15 The details of the research and the
procedures were fully explained to all the subjects, and written
informed consent was obtained from all patients. The study
was approved by the Institutional Research Board of Yuli
Veterans Hospital.2.2. Demographic dataAs shown in Table 1, a total of 590 schizophrenic patients
were recruited for this study, all of whom were inpatients at
Yuli Veterans Hospital. Of those patients, 203 (34.4%) were
40e49 years of age. The mean age of the study subjects was
42.5 10.67 years (range 20e83 years). Overall, 348 (59.0%)
patients were men and 242 (41.0%) were women. Most
patients (34.4%) were senior high school graduates. All study
subjects had been hospitalized for more than 1 year at Yuli
Veterans Hospital.2.3. Serological analysisBlood samples were collected in April 2000 and examined
in the clinical laboratories of Yuli Veterans Hospital. HBV
surface antigen (HBsAg) was tested using a microparticle
enzyme immunoassay (MEIA) method (AxSYM HBsAg (V2);
No.7A40 -22). Antibodies to HCV were assessed in serum
using MEIA (Abbott AxSYM HCV version 3.0; No.3B44-20,
Abbott Laboratories Limited, Diagnostic Division, Abbott
House, Norden Road, Maidenhead, Berkshire, SL6 4XF,
England). Initially reactive assays were repeated in dupli-
cate. At least two reactive results constituted a final result of
an HCV-positive status. Results suggested an overall confir-
mation rate of more than 99% of MEIA-positive tests.
Aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) were also tested, levels below 0.75 mkat/L being
considered to be within the normal range.2.4. Statistical methodsDistributions of HBV and HCV carriers and noninfected
subjects in terms of age, gender, and liver function test results
were examined using c2 tests for categorical variables. All
statistical tests were two-sided, conducted at a significance
level of 0.05. All analyses were performed using SPSS soft-
ware version 15 (International Business Machines Corporation
(IBM), Armonk, New York, United States).
3. Results3.1. HBV prevalenceThe results of HBsAg testing are shown in Table 2. The test
reports were available for 570 out of 590 patients. The
Table 2
The sero-prevalence of HBsAg in chronic institutionally resided schizophrenia
patients.
Hepatitis B surface antigen p value
Negative Positive
n % n %
Gender Female 212 41.5 16 27.1 0.035
Male 299 58.5 43 72.9
Age 20e29 30 5.9 4 6.8 0.353
30e39 154 30.1 24 40.7
40e49 179 35.0 21 35.6
50e59 109 21.3 8 13.6
60e69 32 6.3 1 1.7
70 7 1.4 1 1.7
Education level Elementary school 94 18.9 12 20.3 0.149
Junior high school 119 23.9 21 35.6
Senior high school 174 34.9 20 33.9
College 65 13.1 4 6.8
Others or illiteracy 46 9.2 2 3.4
Aspartate
aminotransferase
level (mkat/L)
< 0.75 495 96.9 57 96.6 0.709
 0.75 16 3.1 2 3.4
Alanine
aminotransferase
level (mkat/L)
< 0.75 415 81.4 40 67.8 0.022
 0.75 95 18.6 19 32.2
History of
alcohol use
No 368 72.2 38 64.4 0.274
Yes 142 27.8 21 35.6
Current
alcohol use
No 505 99.4 59 100.0 1.000
Yes 3 0.6 0 0.0
History of
cigarette use
No 264 51.8 28 47.5 0.625
Yes 246 48.2 31 52.5
Current
cigarette use
No 277 54.5 31 52.5 0.879
Yes 231 45.5 28 47.5
Table 3
The sero-prevalence of anti-HCV in chronic institutionally resided schizo-
phrenia patients.
Anti-hepatitis C virus p value
Negative Positive
n % n %
Gender Female 240 41.6 2 18.2 0.136
Male 337 58.4 9 81.8
Age 20e29 33 5.7 1 9.1 0.249
30e39 180 31.2 4 36.4
40e49 200 34.7 3 27.3
50e59 125 21.7 1 9.1
60e69 32 5.5 1 9.1
 70 7 1.2 1 9.1
Education level Elementary school 110 19.5 0 0.0 0.341
Junior high school 142 25.2 5 45.5
Senior high school 194 34.5 3 27.3
College 68 12.1 2 18.2
Others or illiteracy 49 8.7 1 9.1
Aspartate
aminotransferase
level (mkat/L)
< 0.75 554 97.2 9 81.8 0.042
 0.75 16 2.8 2 18.2
Alanine
aminotransferase
level (mkat/L)
< 0.75 464 81.5 3 27.3 <0.0001
 0.75 105 18.5 8 72.7
History of
alcohol use
No 411 71.4 9 81.8 0.737
Yes 165 28.6 2 18.2
Current
alcohol use
No 570 99.5 11 100.0 1.000
Yes 3 0.5 0 0.0
History of
cigarette use
No 303 52.6 2 18.2 0.050
Yes 273 47.4 9 81.8
Current
cigarette use
No 318 55.4 4 36.4 0.235
Yes 256 44.6 7 63.6
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(12.6%) and 16 females (7.0%). Among the patients positive
for HBsAg, there was no significant difference in age,
educational level, or history of alcohol or cigarette use, except
for gender. Among the patients positive for HBsAg, 72.9%
were males and 27.1% were females ( p¼ 0.035). Two patients
(3.4%) with elevated AST and 19 patients (32.2%) with
elevated ALT were noted. There was no difference in AST
between patients who tested positive or negative for HbsAg
( p¼ 0.709), but disproportionally high levels of ALT were
noted in patients who tested positive for HbsAg ( p¼ 0.022).3.2. HCV prevalenceThe result of anti-HCV testing is shown in Table 3. Anti-
HCV test reports were available for 588 of the 590 patients.
The seroprevalence rate of anti-HCV was 1.9%, including
nine males (2.6%) and two females (0.8%). There was no
significant difference in the demographic data among patients
who were anti-HCV positive. There was a higher proportion
of abnormal AST (81.8%, p¼ 0.042) and ALT (72.7%,
p< 0.0001) levels among anti-HCV-positive patients compared
to anti-HCV-negative patients. Three of 11 patients with anti-
HCV-positive readings had impaired liver function with levels
above two folds the normal upper range (data not shown).3.3. HBV and HCV co-infectionThere was only one patient with concurrent HBV and HCV
infection (0.2%).4. Discussion
Previous epidemiological data indicate that patients with
serious mental illnesses are at increased risk for HBV and
HCV infection.10e12 According to current guidelines,9,16 all
patients with chronic HBV and HCV infection, especially
those with impaired liver function, should be assessed to
determine whether they might benefit from therapy. In our
study, no patient with chronic HBV or HCV infection ever
underwent this treatment evaluation. The burden of HBV and
HCV infections and the consequences may thus be
underestimated.
The prevalence of HBV in Taiwan ranges from 10% to
17.3%, according to different surveys (Table 4).6,17e24 In our
study, the prevalence of HBV among patients with schizo-
phrenia appeared to be lower than that in the general pop-
ulation. The likelihood that an HBV infection will become
chronic depends upon the age at which a person becomes
infected, with young children infected with HBV being most
likely to develop chronic hepatitis.1,25 Most patients with
Table 4
Comparison of the prevalence in the general population in Taiwan.
Trial (year) HBV HCV Notes
Current study (2000) 10.4% 1.8%
Chen and Sung (1978)20 15.0% d Only HBV prevalence
Wu et al (1991)24 d 0.1e34.1% High variation between groups
Sun et al (1999)41 d Mean 2.28% (1.60e19.60%) Only HCV prevalence; high variation between towns
Merican et al (2000)17 > 10.0% 1.0%
Lin et al (2000)23 14.8% 16.7% Difference between ethnicities
Sun et al (2001)47 d 5.4% Only HCV prevalence
Wang et al (2002)18 13.8% 17.0% Data for the southern Taiwanese town where infection is most prevalent
Yang et al (2003)16 d 3.9%
Chen et al (2007)6 17.3% 4.4% 1996e2005; large scale survey
Chen et al (2007)19 12.8% d Only HBV prevalence
Huang et al ((2008)21 d 2.8% Only HCV prevalence
Lai et al (2009)22 6.6e15.1% d Only HBV prevalence
HBV¼ hepatitis B virus; HCV¼ hepatitis C virus.
Table 5
Comparison of prevalence in serious mental illness.
HBV HCV
Current study (2000) 10.35% 1.87%
Said et al (2001)12 7.29% NA Jordan; only HBV
prevalence
Chaudhury et al (1994)8 12.00% NA India; only HBV
prevalence; 5.5 times
the matched control
Rosenberg et al (2001)11 23.40% 19.60% USA; five and 11 times
the overall general
population, respectively
HBV¼ hepatitis B virus; HCV¼ hepatitis C virus.
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transmission that occurred before the implementation of the
national hepatitis B vaccination program in 1984.25
Acute HBV infection may cause acute hepatic failure and
mortality. Several studies have reported that HBV contributes
to 7e32% of the etiology of acute hepatic failure.26e29 It is
reasonable to imply that a proportion of schizophrenic patients
may have died from acute hepatic failure during acute infec-
tion or reactivation, and thus have not been included in our
statistics. In addition, long-term hospitalization may prevent
patients with chronic schizophrenia from exposure to risky
behaviors, such as tattooing, intravenous drug abuse, inap-
propriate sexual contact, ear piercing, etc., thus reducing the
risk for HBV infection.
Furthermore, the prevalence of hepatitis in schizophrenic
patients might have been reduced by the vaccination program
that has been promoted by the Department of Health in
Taiwan since 1984. The program began with free-of-charge
vaccination of newborn babies, and then gradually included
older people. Eventually, all citizens with HBsAg-negative
serum, including institutionalized patients with mental
illness, were offered the vaccination.30,31 Consequently, the
prevalence rate of hepatitis B has declined in Taiwan in recent
years.9,13,16,32e39 This decline in prevalence rate may also be
seen in institutionalized patients with serious mental illness.
The prevalence of HCV varies among studies in normal
populations. Merican et al reported the lowest HCV prevalence
of 1.00%;17 Sun et al reported an HCV prevalence of
1.60e19.60%, with a mean prevalence of 2.28%.40 The prev-
alence of HCV in patients in our study is similar to that seen in
other surveys in Taiwan during the first decade of the 21st
century (Table 4). Wang et al reported the highest prevalence of
approximately 17% in a town in southern Taiwan with the most
elevated HCV prevalence, whereas Lin et al reported a 16.7%
prevalence rate of HCV in Eastern Taiwan, with a range of
3.6e27.5% among different aboriginal villages.23
HCV is less efficiently transmitted by single small-dose percu-
taneous exposures (e.g., accidental needlestick injuries)41,42
or by mucosal exposures to blood or serum-derived fluids
(e.g., birth to an infected mother, sexual contact with aninfected partner).11,41,43 Transmission of HCV is mainly
caused by cross-contamination from reused needles and
syringes, multiple-use medication vials, infusion bags, and
injection drug use devices.44e46 As to how this affects
chronically institutionalized patients with schizophrenia,
HCV transmission may be lower in this population due to
heightened levels of medical attention given to the patients
and their less risky behaviors, as mentioned above.
The prevalences of HBV and HCV in our study were no
higher than the prevalences in other studies investigating
psychiatric patients (Table 5). Said et al reported an HBV
prevalence of 7.29% in patients with serious mental illness.12
Chaudhury et al reported a prevalence rate of 12% of HBV in
mentally ill patients, which was 5.5 times higher than the
equivalent prevalence in the matched controls.8 Rosenberg
et al reported a prevalences of 23.4% for HBV and 19.6% for
HCV in serious mentally ill patients, values that were five and
11 times higher than those in the overall general population,
respectively.11 Sixty-five per cent of patients mentioned in
Rosenbery et al’s study were recruited from the outpatient
clinic, and 75% of patients with HCV infection were self-
reported injection drug users.
These authors concluded that elevated rates within several
risk categories may reflect the poverty, risky environments,
and overall poor health and medical care that are common in
many people with severe mental illness. On the other hand,
279C.-C. Hung et al. / Journal of the Chinese Medical Association 75 (2012) 275e280patients with schizophrenia in the Yuli Veterans Hospital
were housed in open dormitories with medical professionals
on duty, with extensive space provided for leisure and
physical activities.15 The protective, medically supervised
environment may keep these patients from risky behaviors
and thus reduce the rates of infectious disease (Tables 4
and 5).6,8,11,12,16e24,41,47
In conclusion, our study showed that the prevalences of
HBV and HCV among institutionalized patients with chronic
schizophrenia were no higher than those in the general pop-
ulation. The patients recruited in this study were all permanent
residents of the Yuli Veterans Hospital and were considered
to be chronically ill.15 These patients came from not only
neighboring cities, but also the entire country, and could be
representative of the patient population with chronic schizo-
phrenia throughout Taiwan. The commodious environment
and available medical resources of the hospital where the
patients resided might have prevented an elevation of HBVand
HCV infection rates, which is worth further exploration.References
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